About This Test
Imatinib is a Tyrosine kinase inhibitor (TKI) capable of inducing durable hematologic and cytologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develop functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage.
Home Collection
✓ Available
Reports Available In
8 Days
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Submit latest BCR-ABL Quantitative report along with sample.
Imatinib is a targeted therapy (tyrosine kinase inhibitor) commonly used to treat chronic myeloid leukemia (CML) and some gastrointestinal stromal tumors (GISTs). Some patients develop resistance to imatinib due to mutations in the BCR-ABL1 or KIT/PDGFRA genes, which reduce the drug’s effectiveness. IRMA detects these mutations.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
